Avanz Bio Revenue

Pharmaceutical Manufacturing • • 11-20 Employees

Avanz Bio revenue & valuation

Annual revenue	$1,112,215
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$3,600,000
Total funding	No funding

Key Contact at Avanz Bio

Arun Sayani

Founder & Ceo

Company overview

Headquarters	XX
Website	avanzbiollc.com
NAICS	3254
Founded	2011
Employees	11-20

Avanz Bio Email Formats

Avanz Bio uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	42.1%
{first name}@company.com	john@company.com	25.3%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	14.8%
{first name}{last name}@company.com	johndoe@company.com	10.2%
{last name}@company.com	doe@company.com	7.6%

About Avanz Bio

Avanz Bio is an innovative biopharmaceutical company driving the development of novel drug products for treatment of immune and other related diseases using repurposing, incremental innovation technology. The technology is targeted to provide better pharmacokinetic, pharmacodynamics, physicochemical properties, and enable development of known agents for both existing and new indications. The technology involves the generation of novel prodrugs of approved therapeutics by conjugating long chain fatty acids, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and caprylic acid (CPA) with approved therapeutics using ester linkages. The fatty acids used in generating the conjugates are GRAS (Generally Recognized As Safe) listed molecules. Our novel conjugates have the potential of increased efficacy, tissue distribution, safety, compliance and synergic/additive pharmacology of conjugate components. Our approach to drug discovery and clinical development is more efficient and less expensive than conventional small molecule drug research and development. We are implementing this innovative approach to develop a robust pipeline of new medicines addressing unmet medical needs. These novel molecules have robust intellectual property protection including composition of matter, treatment, process, formulation and physical combination claims.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

C-Suite

Manager

Employees by Department

Avanz Bio has 2 employees across 2 departments.

Departments

Number of employees

Funding Data

Avanz Bio has never raised funding before.

Frequently asked questions

Avanz Bio is located in XX.

Avanz Bio generates an estimated annual revenue of $1,112,215. This revenue figure reflects the company's market position and business performance in its industry.

Avanz Bio has an estimated valuation of $3,600,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Avanz Bio was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

Avanz Bio has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Avanz Bio

Arun Sayani

Founder & Ceo

4.8

40,000 users